Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-cash Items (2021 - 2025)

Historic Non-cash Items for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $5.1 million.

  • Amylyx Pharmaceuticals' Non-cash Items rose 3073.07% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 3073.07%. This contributed to the annual value of $3.6 million for FY2024, which is 757.25% down from last year.
  • Amylyx Pharmaceuticals' Non-cash Items amounted to $5.1 million in Q3 2025, which was up 3073.07% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Non-cash Items registered a high of $201.8 million during Q4 2022, and its lowest value of $287000.0 during Q2 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Non-cash Items value was $5.0 million (recorded in 2025), while the average stood at $35.0 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 9513.99% in 2023, then surged by 159698.43% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Non-cash Items stood at $15.6 million in 2021, then surged by 1191.13% to $201.8 million in 2022, then tumbled by 86.3% to $27.6 million in 2023, then tumbled by 87.03% to $3.6 million in 2024, then surged by 40.96% to $5.1 million in 2025.
  • Its Non-cash Items was $5.1 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.1 million in Q1 2025.